Targeted treatment of non-small cell lung cancer

被引:0
|
作者
Scheffler, Matthias [1 ]
Michels, Sebastian [1 ]
Nogova, Lucia [1 ]
机构
[1] Univ Klinikum Koln AoR, Klin Innere Med 1, Ctr Integrierte Onkol CIO Aachen Bonn Koln Dussel, Lung Canc Grp Cologne, Kerpener Str 62, D-50937 Cologne, Germany
来源
INNERE MEDIZIN | 2022年 / 63卷 / 07期
关键词
Mutation; KRAS; EGFR; BRAF; Molecular genetic analysis; Drug resistance; neoplasm; OPEN-LABEL; ACQUIRED-RESISTANCE; INTEGRATED ANALYSIS; 1ST-LINE TREATMENT; EGFR MUTATIONS; CHEMOTHERAPY; MULTICENTER; CRIZOTINIB; PHASE-3; EFFICACY;
D O I
10.1007/s00108-022-01372-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-small cell lung cancer (NSCLC) has made a remarkable development in recent decades with respect to its perception. In the late 1990s it was the "problem child" as the main cause of cancer with increasing tendencies, especially in women and with a pronounced stigmatization. It is now the role model as a biologically rational targeted treatment based on molecular dependencies of the tumor with a vast improvement of the traditionally poor survival times. Molecular tumor boards have long followed the NSCLC example in the assessment of targeted treatment approaches for other tumor entities. This review article gives an overview of the current possibilities for targeted treatment of NSCLC, which nowadays are applicable for nearly one third of all patients with NSCLC.
引用
收藏
页码:700 / 708
页数:9
相关论文
共 50 条
  • [41] Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review
    Chen, Jiayan
    Xu, Chunwei
    Lv, Jiawen
    Lu, Wanjun
    Zhang, Yixue
    Wang, Dong
    Song, Yong
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (04) : 895 - 908
  • [42] Second generation ALK inhibitors in non-small cell lung cancer: Systemic review
    Viala, Marie
    Brosseau, Solenn
    Planchard, David
    Besse, Benjamin
    Soria, Jean-Charles
    BULLETIN DU CANCER, 2015, 102 (04) : 381 - 389
  • [43] The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review
    Hsu, Robert
    Benjamin, David J. J.
    Nagasaka, Misako
    CANCERS, 2023, 15 (14)
  • [44] Experience with erlotinib in the treatment of non-small cell lung cancer
    Landi, Lorenza
    Cappuzzo, Federico
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (04) : 146 - 163
  • [45] MEK inhibitors for the treatment of non-small cell lung cancer
    Han, Jing
    Liu, Yang
    Yang, Sen
    Wu, Xuan
    Li, Hongle
    Wang, Qiming
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [46] Safety of gefitinib in non-small cell lung cancer treatment
    Hsiue, Emily Han-Chung
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (07) : 993 - 1000
  • [47] Afatinib for the treatment of metastatic non-small cell lung cancer
    Joshi, Monika
    Rizvi, Syed M.
    Belani, Chandra P.
    CANCER MANAGEMENT AND RESEARCH, 2015, 7 : 75 - 82
  • [48] Personalized treatment of advanced non-small cell lung cancer
    Koehler, J.
    Schuler, M.
    ONKOLOGE, 2011, 17 (08): : 702 - +
  • [49] Treatment of stage IV non-small cell lung cancer with driver mutations
    Michels, Sebastian
    Wolf, Juergen
    ONKOLOGE, 2018, 24 (12): : 983 - 991
  • [50] Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer
    Chhouri, Houssein
    Alexandre, David
    Grumolato, Luca
    CANCERS, 2023, 15 (02)